• Home
  • News
    • Editorial
    • MD(e)B(unker)
    • Related Researches
      • Di Bella's Foundation
      • 1960-1969
      • 1970-1979
      • 1980-1989
      • 1990-1999
      • 2000-2009
      • 2010-2019
      • 2020-2029
    • Science news
    • Scientific Documentation
  • About us...
    • Biography
    • Bibliography
  • The Method
    • Di Bella's Method!
    • 1998 Trial!
  • Media
    • Video Publications
    • News-PapersNews-Papers
      • Press
    • TestimonialTestimonial
      • Testimonies
    • Video GalleryVideo Gallery
      • Congresses
      • Video Testimonies
      • TV & C.
  • Case History
    • Medical reports
      • Lung
      • Lymphomas
        • Non-Hodgkin Lymphomas
        • Hodgkin Lymphomas
      • Mediastinum
      • Mesothelioma
      • Myeloma
      • Pancreas
      • Scientific Publications
  • F.A.Q.
  • Useful Links
    • User Side
      • Vademecum
    • CouponChief - Resources for Cancer Patients
  • Contact Us
Home page   News   Related Researches  
Title Created Date
Synergy in ERK activation by cytokine receptors and tyrosine kinase growth factor receptors 02 March 2014
Overexpression of P53 protein and local hGH, IGF-I, IGFBP-3, IGFBP-2 and PRL secretion by human breast cancer explants 02 March 2014
Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor 25 February 2014
Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland 25 February 2014
Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells 20 February 2014
New concepts in prolactin biology 20 February 2014
Somatostatin in breast cancer 19 February 2014
Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells 19 February 2014
Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124] 19 February 2014
Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma 12 February 2014
Display # 

Page 164 of 172

  • Start
  • Prev
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • Next
  • End

Search

Follow us...

Latest

  • Melatonin induces apoptosis through a caspase-dependent but reactive oxygen species-independent mechanism in human leukemia Molt-3 cells
  • Melatonin is an appropriate candidate for breast cancer treatment: Based on known molecular mechanisms
  • Key aspects of melatonin physiology: Thirty years of research
  • Somatostatin in oncology, the overlooked evidences
  • Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy (Review)
  • Key aspects of melatonin physiology: 30 years of research
  • Melatonin anticancer effects: Review
  • Osteogenesis from Dental Pulp Derived Stem Cells: A Novel Conditioned Medium Including Melatonin within a Mixture of Hyaluronic, Butyric, and Retinoic Acids
  • Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers
  • Mechanisms of antineoplastic action of somatostatin analogs
  • Evaluation of radio-protective effect of melatonin on whole body irradiation induced liver tissue damage
  • Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives
  • Effects of somatostatin, curcumin, and quercetin on the fatty acid profile of breast cancer cell membranes
  • Effects of Somatostatin and Vitamin C on the Fatty Acid Profile of Breast Cancer Cell Membranes
  • Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression
  • Growth Hormone's Links to Cancer
  • The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity
  • The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature

Most Read

  • The Di Bella Method (DBM)
  • About melatonin - 1996
  • All-trans-retinoic acid and cancer
  • Biography
  • Chronic Lymphocytic Leukemia: 4 patients, long-lasting remission
  • The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer
  • Somatostatin in oncology, the overlooked evidences
  • Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage
  • How effective is chemo therapy?
  • Complete objective response to biological therapy of plurifocal breast carcinoma
  • Bibliography
  • Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report
  • Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report
  • Vademecum
  • Frequently Asked Questions
  • Declaration recommends eliminate the use of Impact factor for research evaluation
  • Non–Small-Cell Lung Cancer Patients with Low Performance Status: study on 28 patients
  • Breast cancer: study on 122 cases. The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer